[quick news] on June 13, 2018, the tetravalent influenza vaccine was approved for the first time in China

Our reporter learned from the State Drug Administration on June 11 that the tetravalent influenza virus split vaccine was approved for listing in China to prevent the infection of influenza virus in people aged 3 and over This is the first quadrivalent influenza vaccine on the market in China Before that, all influenza vaccines on the market in China were trivalent influenza vaccines Http://news.scienceet.cn/dz/dznews_photo.aspx sun Dawen was elected as an academician of the International Academy of refrigeration sciences The reporter learned from South China University of technology that sun Dawen, a professor of the University, recently received the academician certificate issued by the International Academy of refrigeration sciences The International Academy of refrigeration Sciences aims to solve the basic and application problems in refrigeration and Cryogenics Engineering, air conditioning, food processing and storage, cryomedicine, etc Academician honor of the International Academy of refrigeration Sciences represents the highest honor in the field of refrigeration Http://news.scienceet.cn/htmlnews/2018/6/414221.shtm nearly a thousand Chinese majors have entered the "first square array" of global engineering education Recently, the reporter learned from the Ministry of education that by the end of 2017, the higher education teaching evaluation center of the Ministry of education and China Engineering Education Professional Certification Association had certified 846 engineering majors in 198 universities in China Through professional certification, the quality of these specialties has achieved international substantial equivalence and has entered the "first square array" of global engineering education Http://www.moe.edu.cn/s78/a08/moe_/201806/t20180612_.html FDA approved drug venclexta and rituxan for leukemia treatment Recently, abbvie and Genentech announced that the US FDA has approved the combination of venclexta (venetoclax) and rituxan (rituximab), the two companies' heavyweight drugs, to treat patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphocytoma (SLL) This approved combination therapy is expected to bring hope to patients Https://www.gene.com/media/press-releases/14728/2018-06-08/genentech-announcements-fda-approval-for-ven new Pfizer drug talazoparib has been given priority review by the US FDA for the treatment of advanced breast cancer Recently, Pfizer, a global pharmaceutical giant, announced that the U.S Food and Drug Administration (FDA) accepted the talazoparib new drug application (NDA) developed by it and granted priority review qualification This NDA submission is based on the results of the clinical trial embraca This trial evaluated the efficacy of talazoparib in patients with HER2 negative locally advanced or metastatic breast cancer (MBC) of a BRCA mutation (gbrcam) compared with chemotherapy At the same time, the European Drug Administration (EMA) has also accepted talazoparib's marketing authorization application (MAA) https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_and_european_medicines_agency_accept_regulatory_submissions_for_review_of_talazoparib_for_metastatic_breast_cancer_patients_with_an_inherited_brca_mutation-0